ArticleMicrobiology spectrum2023
A novel coli myophage and antibiotics synergistically inhibit the growth of the uropathogenic
Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Rational Design of a Phage Cocktail for Effective Control of Multidrug-Resistant UropathogenicAntibiotics (Basel, Switzerland) · 2026Article
- Temperature-dependent coliphage induces distinct temporal bacterial morphological dynamics during infection.Microbiology spectrum · 2026Article
- Combating multidrug-resistant uropathogenic E. coli using lytic phages, enhancing antibiotic synergy and inhibiting biofilms.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- PSK1, a bacteriophage with antibacterial activity against extended-spectrum-beta-lactamase-producing Escherichia coli sequence type 131 with serotype O25:H4.Archives of virology · 2025Article
- Rapid formulation of a genetically diverse phage cocktail targeting uropathogenic Escherichia coli infections using the UTI89 model.Scientific reports · 2025Article
- Review
- Synergy of lytic phage pB23 and meropenem combination against carbapenem-resistantAntimicrobial agents and chemotherapy · 2024Article
- Nucleus-forming jumbophage PhiKZ therapeutically outcompetes non-nucleus-forming jumbophage Callisto.iScience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
importancePhage therapy has recently been in the spotlight as a viable alternative therapy for bacterial infections. However, several studies have raised concerns about the emergence of phage resistance that occurs during treatment, making the therapy not much effective. Here, we present the discovery of a novel
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.